Blue Earth Diagnostics
Blue Earth Diagnostics is an Oxford-headquartered subsidiary of Bracco Imaging that develops and commercializes PET radiopharmaceuticals — Axumin and POSLUMA — for cancer diagnostics, serving nuclear medicine, oncology, and urology professionals in the US, Europe, and Asia-Pacific.
- Company typePrivate
- Founded2014
- HeadquartersOxford, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Blue Earth Diagnostics does
Blue Earth Diagnostics is a UK-headquartered molecular imaging company that develops and commercializes PET radiopharmaceuticals for cancer diagnostics. Founded in 2014 in Oxford and operating as an indirect subsidiary of Bracco Imaging S.p.A. since August 2019, the company is focused exclusively on oncology imaging across prostate cancer, brain cancer, and multiple solid tumors. Its core technology platform centers on radiohybrid PSMA-targeted agents licensed exclusively worldwide from Scintomics, FAP-targeted imaging agents partnered with Philochem AG, and fluciclovine chemistry originally invented at Emory University. The commercial portfolio comprises two FDA-approved products: Axumin (fluciclovine F 18), approved in May 2016 for recurrent prostate cancer imaging and subsequently EMA-approved in May 2017; and POSLUMA (flotufolastat F 18), approved in May 2023 as the first radiohybrid PSMA-targeted PET imaging agent for prostate cancer and subsequently approved in South Korea and Taiwan through local marketing authorization holders.
The company's revenue model combines one-time product sales of approved imaging agents with licensing and royalty income from regional marketing authorization holders in Asia. Distribution relies on exclusive US manufacturing and supply through PETNET Solutions, a Siemens Healthineers subsidiary, plus European supply through Advanced Accelerator Applications (a Novartis company) and additional regional radiopharmacy distributors (Seibersdorf, IASON, M2i, Norsk medisinsk syklotronsenter). Reimbursement is supported by NCCN and EAU guideline inclusion for both Axumin and POSLUMA, and a CMS Transitional Pass-Through Payment Reimbursement Code for POSLUMA effective October 2023. The pipeline extends the franchise into brain metastases imaging (fluciclovine, Phase 3 REVELATE trial completed enrollment), FAP-targeted imaging for multiple solid tumors (Phase 1 complete), and — via a 2020 expansion of the Scintomics license and the 2021 formation of sister company Blue Earth Therapeutics — into therapeutic applications of the radiohybrid platform.
The customer base is healthcare professionals in nuclear medicine, radiology, urology, and oncology, reached through enterprise field sales and an event-driven go-to-market focused on major medical conferences (ASCO GU, SNMMI, ASTRO, EAU, AUA, RSNA, EANM). Named end customers include hospital systems and regional imaging centers (e.g., Northside Hospital Atlanta, Northern California PET Imaging Center), with commercial distribution extending across hundreds of US PET imaging sites via PETNET and additional European and Asia-Pacific territories via local partners. The company employs 101-250 staff across offices in Oxford (UK headquarters), Needham, MA (US headquarters opened April 2025), and Dublin (European marketing authorization holder).
Blue Earth Diagnostics firmographics
Firmographics- Name
- Blue Earth Diagnostics
- Legal name
- Blue Earth Diagnostics Limited
- Website
- https://blueearthdiagnostics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Blue Earth Diagnostics is an Oxford-headquartered subsidiary of Bracco Imaging that develops and commercializes PET radiopharmaceuticals — Axumin and POSLUMA — for cancer diagnostics, serving nuclear medicine, oncology, and urology professionals in the US, Europe, and Asia-Pacific.
- Ownership category
- akta.pro rank
Blue Earth Diagnostics industry classification
Industry- Product category
- PET Radiopharmaceuticals
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA)
- akta.pro secondary industries
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG)
Keywords
Where Blue Earth Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Blue Earth Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Axumin (fluciclovine F 18) Sales: Commercial sales of FDA-approved and EMA-approved PET imaging agent for recurrent prostate cancer detection. Marketed in the US, Europe, and UK through direct sales and distribution partnerships.
- POSLUMA (flotufolastat F 18) Sales: Commercial sales of FDA-approved radiohybrid PSMA-targeted PET imaging agent for prostate cancer. Also approved in South Korea (Prostaseek) and Taiwan (POSLUMA) through local marketing authorization holders.
- Licensing and Royalty Income: Revenue from licensing of proprietary technologies to regional partners. Marketing authorization holders in South Korea (DuChemBio) and Taiwan (Global Medical Solutions) pay royalties for flotufolastat F 18 distribution rights.
Go-to-market motion2 records
Distribution channels10 records
Marketing channels6 records
Blue Earth Diagnostics product offering
Product offeringCore offering
Blue Earth Diagnostics develops, manufactures, and commercializes fluorine-18 labeled PET radiopharmaceuticals used in cancer imaging. Its commercially available products include Axumin (fluciclovine F 18) for detecting recurrent prostate cancer and POSLUMA (flotufolastat F 18) for prostate cancer imaging. The company also maintains a development pipeline including 18F-rhPSMA-7.3 and fibroblast activation protein (FAP)-targeted agents.
Product overview
Blue Earth Diagnostics is a molecular imaging company developing and commercialising PET radiopharmaceuticals for cancer diagnostics. Their portfolio includes two marketed products: Axumin (fluciclovine F 18), a PET imaging agent for recurrent prostate cancer approved in the US (2016), Europe (2017), and UK; and POSLUMA (flotufolastat F 18), a radiohybrid PSMA-targeted PET agent approved in the US (2023), South Korea (as Prostaseek), and Taiwan. The company maintains an active pipeline including 18F-rhPSMA-7.3 (completed Phase 3 SPOTLIGHT and LIGHTHOUSE trials) and FAP-targeted imaging technology (Phase 1 completed). Their clinical focus is exclusively on oncology, with products used in PET imaging to detect and guide treatment decisions for prostate cancer and other solid tumors.
Differentiator
Problem solved
Functional benefit
Brands
- Blue Earth Therapeutics: Sister company to Blue Earth Diagnostics, part of the Bracco family of companies, focused on advancement of next generation targeted radiotherapeutics to treat patients with cancer.
Products and services
- Axumin (fluciclovine F 18)
Quantifiable outcome
- 64% of patients had change in management following Axumin PET/CT scan (FALCON trial results, 2019)
- +3 more outcomes
Companies that use Blue Earth Diagnostics
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles1 record
Blue Earth Diagnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Blue Earth Diagnostics partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered major, core and regional.
- Siemens HealthineersmajorAgreement to share POSLUMA (flotufolastat F 18) clinical data to support AI-based algorithms development. Builds on existing manufacturing partnership with PETNET Solutions, a Siemens Healthineers company.
- Sinotau Pharmaceutical GroupmajorCollaboration to bring flotufolastat (18F) injection, a prostate cancer PET diagnostic imaging agent, to China. Announced October 2023, expanding geographic reach to one of the largest pharmaceutical markets.
- Siemens HealthineersmajorData-sharing agreement with Siemens Healthineers and University Hospital of Technical University of Munich for 18F-rhPSMA-7.3 clinical data to support AI-based algorithms development.
- Bracco Imaging S.p.A.coreBracco Imaging, a global leader in diagnostic imaging operating in over 90 markets worldwide, acquired Blue Earth Diagnostics as an indirect subsidiary in August 2019. The acquisition leverages Bracco's diagnostics modalities, global competencies, portfolio, and financial resources while Blue Earth Diagnostics retains its established name and leadership team.
- IASON Sp. z o.o.regionalAppointed to manufacture and distribute Axumin (fluciclovine 18F) in Poland, expanding European market access.
- Scintomics GmbHcoreBlue Earth Diagnostics acquired exclusive worldwide rights to radiohybrid PSMA-targeted agents (rhPSMA) from Scintomics. In 2020, the partnership expanded to include exclusive worldwide rights to therapeutic applications of the novel radiohybrid technology. Scintomics CEO Jan Niclas Wester noted Blue Earth Diagnostics' remarkable speed in getting products to market.
- Seibersdorf LaboratoriesregionalManufacturing and distribution agreements for Axumin (fluciclovine 18F) for PET imaging of recurrent prostate cancer in selected territories.
- Advanced Accelerator Applications (Novartis)majorEuropean manufacturing and distribution agreements for Axumin. AAA, now part of Novartis following acquisition, provides radiopharmaceutical manufacturing capabilities across European markets.
- M2iregionalAppointed to manufacture and distribute Axumin in Ireland.
- PETNET Solutions (Siemens Healthineers)coreExclusive US commercial manufacturing and distribution agreement for Axumin (fluciclovine F 18) signed in 2015, with commercial availability announced June 2016. New supply agreement signed in 2020 covering Axumin and investigational rhPSMA-7.3. Commercial availability of POSLUMA announced June 2023 through PETNET network.
- Norsk medisinsk syklotronsenter ASregionalManufacturing and distribution partnership for fluciclovine (18F) in Norway.
- Philochem AGcorePartnership for development of FAP (Fibroblast Activation Protein) targeting organic ligand for diagnostic imaging applications. Philochem completed Phase 1 clinical trial and Blue Earth Diagnostics assumed continued development and commercialization responsibilities. Prof. Dr. Dario Neri expressed excitement about results collected with the FAP imaging agent.
- Technical University of MunichcoreResearch partnership for rhPSMA technology development. Professor Hans Jürgen Wester and Dr. Matthias Eiber from TUM's Department of Nuclear Medicine collaborated on radiohybrid technology. Data-sharing agreement established with Siemens Healthineers and TUM in 2022 for AI-based algorithm development using 18F-rhPSMA-7.3 clinical data.
Scale indicators5 records
Recent moves11 records
Expansion highlights6 records
Blue Earth Diagnostics competitors and assessment
Company assessmentDirect peers
- Curium: Curium is a global nuclear medicine company producing SPECT and PET radiopharmaceuticals, including PSMA-targeted agents. It competes head-to-head with Blue Earth Diagnostics in prostate cancer imaging and shares a similar radiopharmacy-led distribution model.
- Telix Pharmaceuticals: Telix develops and commercializes radiopharmaceuticals including Illuccix (Ga-68 PSMA-11) for prostate cancer imaging. It directly competes with Blue Earth Diagnostics' Axumin and POSLUMA in the prostate cancer PET imaging market and pursues a similar theranostic strategy.
- Lantheus Holdings: Lantheus is a direct competitor in PSMA-targeted PET imaging, marketing Pylarify (piflufolastat F 18) for prostate cancer. It is a comparable radiopharmaceutical/diagnostic imaging company with overlapping product, customer base, and commercial model in oncology imaging.
Broad incumbents
- Bracco Imaging: Bracco Imaging is the parent company of Blue Earth Diagnostics and a global leader in diagnostic imaging with operations in over 90 markets. It is comparable as a peer through its imaging agent portfolio (e.g., contrast media) and as the parent providing commercialization infrastructure.
- GE HealthCare: GE HealthCare is a broad incumbent in diagnostic imaging with PET/CT scanners and historically operated a radiopharmaceutical business from which Blue Earth Diagnostics' technology was originally licensed. It is also a major competitor/partner via its PETNET Solutions radiopharmacy network.
- Siemens Healthineers: Siemens Healthineers operates the PETNET Solutions radiopharmacy network that distributes Blue Earth Diagnostics' products in the US. It is a broad incumbent in imaging equipment and infrastructure (PET/CT, SPECT), with AI partnerships with Blue Earth Diagnostics for imaging algorithm development.
- Novartis (Advanced Accelerator Applications): Novartis owns AAA, a major radiopharmaceutical company offering PSMA and other nuclear medicine products (e.g., Lutathera, Pluvicto). AAA is also Blue Earth Diagnostics' European distribution partner for Axumin, making it both a partner and competitor across diagnostic and therapeutic nuclear medicine.
Emerging players
- Blue Earth Therapeutics: Blue Earth Therapeutics is the sister company to Blue Earth Diagnostics, also owned by Bracco, focused on therapeutic applications of the radiohybrid platform. It is comparable as an emerging player in radioligand therapy leveraging shared IP from the Scintomics partnership.
- Philochem AG: Philochem AG is a Swiss biotechnology company developing FAP-targeted radioligands. It is a partner to Blue Earth Diagnostics on FAP imaging agents and is comparable as an emerging player in the same targeting-modality space.
- Scintomics GmbH: Scintomics is the licensor of rhPSMA technology to Blue Earth Diagnostics and develops radiohybrid PSMA agents. It is comparable as an emerging radiopharmaceutical developer whose IP forms the basis of Blue Earth Diagnostics' flagship platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key highlights7 records
Customer concentration
Blue Earth Diagnostics social profiles
Digital presenceBlue Earth Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Blue Earth Diagnostics leadership team
Management profileNumber of profiles
Blue Earth Diagnostics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Blue Earth Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Blue Earth Diagnostics
What does Blue Earth Diagnostics do?
Blue Earth Diagnostics develops, manufactures, and commercializes fluorine-18 labeled PET radiopharmaceuticals used in cancer imaging. Its commercially available products include Axumin (fluciclovine F 18) for detecting recurrent prostate cancer and POSLUMA (flotufolastat F 18) for prostate cancer imaging. The company also maintains a development pipeline including 18F-rhPSMA-7.3 and fibroblast activation protein (FAP)-targeted agents.
Is Blue Earth Diagnostics a public or private company?
Blue Earth Diagnostics is a private company. It is classified as corporate owned and is currently operating.
When was Blue Earth Diagnostics founded?
Blue Earth Diagnostics was founded in 2014. It employs 101 to 250 people.
Where is Blue Earth Diagnostics based?
Blue Earth Diagnostics is headquartered in Oxford, United Kingdom, in the Europe region.
How does Blue Earth Diagnostics make money?
Three revenue lines are on record. Axumin (fluciclovine F 18) Sales are the primary driver. The others are POSLUMA (flotufolastat F 18) Sales and licensing and Royalty Income.
Who are Blue Earth Diagnostics's main competitors?
Direct peers on record are Curium, Telix Pharmaceuticals and Lantheus Holdings. Broad incumbents are Bracco Imaging, GE HealthCare, Siemens Healthineers and Novartis (Advanced Accelerator Applications). Emerging players are Blue Earth Therapeutics, Philochem AG and Scintomics GmbH.
Does Blue Earth Diagnostics have an API?
No public API is recorded for Blue Earth Diagnostics.
What industry is Blue Earth Diagnostics in?
Blue Earth Diagnostics's product category is PET Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAA, Diagnostic Radiopharmaceuticals (SPECT/PET Tracers), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 325413 and its SIC code is 2835.